UK firm Physiomics has signed an agreement with Sareum, The Institute of Cancer Research and Cancer Research Technology to provide silico simulations to support cancer drug development.
Physiomics will extend its modelling expertise in biological processes to simulate the effect of cancer drugs.
The three-month research programme will focus on finalising dose schedules and will be funded from the proceeds of a commercial deal.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development.
Share this article
